- Pfaller MA, Diekema DJ. Epidemiology of invasive mycoses in North America. Critical reviews in
microbiology. 2010;36(1):1-53.
2. Horn DL, Neofytos D, Anaissie EJ, Fishman JA, Steinbach WJ, Olyaei AJ, et al. Epidemiology
and outcomes of candidemia in 2019 patients: data from the prospective antifungal therapy alliance
registry. Clinical infectious diseases. 2009;48(12):1695-703.
3. Badiee P, Kordbacheh P, Alborzi A, Malekhoseini SA. Invasive fungal infection in renal
transplant recipients demonstrated by panfungal polymerase chain reaction. Exp Clin Transplant.
2007;5(1):624-9.
4. Blumberg HM, Jarvis WR, Soucie JM, Edwards JE, Patterson JE, Pfaller MA, et al. Risk factors
for candidal bloodstream infections in surgical intensive care unit patients: the NEMIS prospective
multicenter study. Clinical Infectious Diseases. 2001;33(2):177-86.
5. Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB. Nosocomial
bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide
surveillance study. Clinical infectious diseases. 2004;39(3):309-17.
6. Dornbusch HJ, Manzoni P, Roilides E, Walsh TJ, Groll AH. Invasive fungal infections in
children.Pediatr Infect Dis J 2009;28(8):734-7.
7. Bille J, Marchetti O, Calandra T. Changing face of health-care associated fungal infections. Curr
Opin Infect Dis 2005;18:314-9.
8. Garcia-Vidal C, Upton A, Kirby KA, Marr KA. Epidemiology of invasive mold infections in
allogeneic stem cell transplant recipients: biological risk factors for infection according to time after
transplantation. Clinical Infectious Diseases. 2008;47(8):1041-50.
9. Neofytos D, Fishman JA, Horn D, Anaissie E, Chang CH, Olyaei A, et al. Epidemiology and
outcome of invasive fungal infections in solid organ transplant recipients. Transplant Infectious Disease.
2010;12(3):220-9.
10. Dimopoulos G, Matthaiou DK, Moussas N, Apostolopoulou O, Arabatzis G, Velegraki A, et al.
Pathogenesis of Aspergillosis in Humans. Human Emerging and Re‐emerging Infections: Viral and
Parasitic Infections. 2015:967-84.
11. Perfect JR, Cox GM, Lee JY, Kauffman CA, De Repentigny L, Chapman SW, et al. The impact
of culture isolation of Aspergillus species: a hospital-based survey of aspergillosis. Clinical Infectious
Diseases. 2001;33(11):1824-33.
12. Schabereiter-Gurtner C, Selitsch B, Rotter ML, Hirschl AM, Willinger B. Development of novel
real-time PCR assays for detection and differentiation of eleven medically important Aspergillus and
Candida species in clinical specimens. Journal of clinical microbiology. 2007;45(3):906-14.
13. Badiee P, Alborzi A, Shakiba E, Ziyaeyan M, Pourabbas B. Molecular diagnosis of Aspergillus
endocarditis after cardiac surgery. Journal of medical microbiology. 2009;58(2):192-5.
14. Bretagne S, Costa JM. Towards a molecular diagnosis of invasive aspergillosis and disseminated
candidosis. FEMS Immunol Med Microbiol 2005;45(3):361-8.
15. De Pauw B, Walsh TJ, Donnelly JP, Stevens DA, Edwards JE, Calandra T, et al. Revised
definitions of invasive fungal disease from the European organization for research and treatment of
cancer/invasive fungal infections cooperative group and the national institute of allergy and infectious
diseases mycoses study group (EORTC/MSG) consensus group. Clinical infectious diseases.
2008;46(12):1813-21.
16. Choi J-K, Cho S-Y, Yoon S-S, Moon J-H, Kim S-H, Lee J-H, et al. Epidemiology and Risk
Factors for Invasive Fungal Diseases among Allogeneic Hematopoietic Stem Cell Transplant Recipients
in Korea: Results of “RISK” Study. Biology of Blood and Marrow Transplantation. 2017;23(10):1773-9.
17. Yapar N. Epidemiology and risk factors for invasive candidiasis. Therapeutics and clinical risk
management. 2014;10:95.
18. Badiee P, Badali H, Boekhout T, Diba K, Moghadam AG, Nasab AH, et al. Antifungal
susceptibility testing of Candida species isolated from the immunocompromised patients admitted to ten
university hospitals in Iran: comparison of colonizing and infecting isolates. BMC infectious diseases.
2017;17(1):727.
19. Mello E, Posteraro B, Vella A, De Carolis E, Torelli R, D'Inzeo T, et al. Susceptibility testing of
common and uncommon Aspergillus species against posaconazole and other mold-active antifungal
azoles using the Sensititre method. Antimicrobial agents and chemotherapy. 2017:AAC. 00168-17.
- 20. Badiee P, Alborzi A, Moeini M, Haddadi P. Antifungal susceptibility of the Aspergillus species
by Etest and CLSI reference methods. Archives of Iranian medicine. 2012;15(7):429.
21. Alam FF, Mustafa AS, Khan ZU. Comparative evaluation of (1, 3)-β-D-glucan, mannan and
anti-mannan antibodies, and Candida species-specific snPCR in patients with candidemia. BMC
infectious diseases. 2007;7(1):103.
22. Hao W, Pan Y-X, Ding Y-Q, Xiao S, Yin K, Wang Y-D, et al. Well-characterized monoclonal
antibodies against cell wall antigen of Aspergillus species improve immunoassay specificity and
sensitivity. Clinical and Vaccine Immunology. 2008;15(2):194-202.
23. Mikulska M, Furfaro E, Viscoli C. Biomarkers for diagnosis and follow-up of invasive
candidiasis: a brief review of the ECIL recommendations. Current Fungal Infection Reports.
2012;6(3):192-7.
24. White PL, Archer AE, Barnes RA. Comparison of non-culture-based methods for detection of
systemic fungal infections, with an emphasis on invasive Candida infections. Journal of clinical
microbiology. 2005;43(5):2181-7.
25. White PL, Perry MD, Barnes RA. An update on the molecular diagnosis of invasive fungal
disease. FEMS microbiology letters. 2009;296(1):1-10.
26. Badiee P, Kordbacheh P, Alborzi A, Zakernia M, Haddadi P. Early detection of systemic
candidiasis in the whole blood of patients with hematologic malignancies. Jpn J Infect Dis. 2009;62(1):1-
5.
27. Hope W, Morton A, Eisen DP. Increase in prevalence of nosocomial non-Candida albicans
candidaemia and the association of Candida krusei with fluconazole use. Journal of Hospital Infection.
2002;50(1):56-65.
28. Girmenia C, Martino P, De Bernardis F, Gentile G, Boccanera M, Monaco M, et al. Rising
incidence of Candida parapsilosis fungemia in patients with hematologic malignancies: clinical aspects,
predisposing factors, and differential pathogenicity of the causative strains. Clinical Infectious Diseases.
1996;23(3):506-14.
29. Trofa D, Gácser A, Nosanchuk JD. Candida parapsilosis, an emerging fungal pathogen. Clinical
microbiology reviews. 2008;21(4):606-25.
30. Tan TY, Tan AL, Tee N, Ng L. A retrospective analysis of antifungal susceptibilities of Candida
bloodstream isolates from Singapore hospitals. Ann Acad Med Singapore. 2008;37(10):835-40.
31. Pagano L, Caira M, Candoni A, Offidani M, Fianchi L, Martino B, et al. The epidemiology of
fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study. Haematologica.
2006;91(8):1068-75.
32. Zaoutis TE, Heydon K, Chu JH, Walsh TJ, Steinbach WJ. Epidemiology, outcomes, and costs of
invasive aspergillosis in immunocompromised children in the United States, 2000. Pediatrics.
2006;117(4):e711-e6.
33. Badiee P, Zareifar S, Haddadi P, Jafarian H. Incidence of Fungal Infections in Pediatric
Patients with Hematologic Neoplasms. Archives of Pediatric Infectous Disease .2017;5(3): :e41317.
|
